59923-17-0

Basic information

• Product Name: 3-nitro-N-(pyridin-2-yl)benzenesulfonamide
• Synonyms: 3-nitro-N-(pyridin-2-yl)benzenesulfonamide
• CAS NO: 59923-17-0
• Molecular Weight: 279.276
• Mol File: 59923-17-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-nitro-N-(pyridin-2-yl)benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-nitro-N-(pyridin-2-yl)benzenesulfonamide(59923-17-0)
• EPA Substance Registry System: 3-nitro-N-(pyridin-2-yl)benzenesulfonamide(59923-17-0)

Safety Data

• Hazardous Substances Data: 59923-17-0(Hazardous Substances Data)

Upstream product

• 504-29-0 2-aminopyridine 
• 121-51-7 3-nitrobenzenesulphonyl chloride 

Downstream Products

• 873383-07-4 3-amino-benzenesulfonic acid-[2]pyridylamide 

Relevant articles and documents

AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES

The invention relates to new compounds with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers, neurodegenerative diseas

Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains

BRD4, characterized by two acetyl-lysine binding bromodomains and an extra-terminal (ET) domain, is a key chromatin organizer that directs gene activation in chromatin through transcription factor recruitment, enhancer assembly, and pause release of the RNA polymerase II complex for transcription elongation. BRD4 has been recently validated as a new epigenetic drug target for cancer and inflammation. Our current knowledge of the functional differences of the two bromodomains of BRD4, however, is limited and is hindered by the lack of selective inhibitors. Here, we report our structure-guided development of diazobenzene-based small-molecule inhibitors for the BRD4 bromodomains that have over 90% sequence identity at the acetyl-lysine binding site. Our lead compound, MS436, through a set of water-mediated interactions, exhibits low nanomolar affinity (estimated Ki of 30-50 nM), with preference for the first bromodomain over the second. We demonstrated that MS436 effectively inhibits BRD4 activity in NF-κB-directed production of nitric oxide and proinflammatory cytokine interleukin-6 in murine macrophages. MS436 represents a new class of bromodomain inhibitors and will facilitate further investigation of the biological functions of the two bromodomains of BRD4 in gene expression.